TAK 802

Drug Profile

TAK 802

Latest Information Update: 26 Aug 2005

Price : $50

At a glance

  • Originator Takeda
  • Class Urologics
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Urinary incontinence

Most Recent Events

  • 29 Apr 2005 Discontinued - Phase-II for Urinary incontinence in Japan (unspecified route)
  • 05 Apr 2004 A preclinical study has been added to the pharmacokinetics and Genitourinary Disorders pharmacodynamics sections
  • 10 Nov 2003 Phase-II clinical trials in urinary incontinence in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top